{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:52:27Z","timestamp":1793836347233,"version":"4.6.1"},"reference-count":45,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Richter transformation (RT) is a rare complication of chronic lymphocytic leukemia (CLL) that has dismal outcomes. Upregulation of PD-1\/PD-L1 drives immunological evasion in patients with RT. We hypothesized that combining nivolumab, a PD-1 blocking antibody, with the BTK inhibitor (BTKi) ibrutinib could potentiate tumor-cell killing. We conducted an investigator-initiated phase 2 clinical trial to assess the efficacy of combined nivolumab and ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL) RT and CLL. Patients included were \u226518 years of age with adequate hepatic and renal function. Patients received nivolumab every 2 weeks of a 4-week cycle for a maximum of 24\u00a0cycles. A standard dose ibrutinib was initiated from cycle 2 onward and continued daily until progression. For patients who were already on ibrutinib at the time of study entry, the same was continued while nivolumab was initiated. A total of 24 patients with RT with a median age of 64.5 years (range, 47-88) were enrolled. Ten patients (42%) had received prior treatment for RT and 13 patients (54%) had received a prior BTKi. A total of 10 patients (42%) responded with a median duration of response of 15\u00a0months. The median overall survival was 13 months. Four of 24 (17%) patients had checkpoint inhibition\u2013related immunological toxicities. In the CLL cohort, 10 patients were enrolled, of whom 3 patients converted from partial to complete remission; 1 patient had a grade 2 immunological toxicity. Combined nivolumab and ibrutinib is an active regimen for patients with DLBCL RT with an overall response rate of 42%. Given the limited treatment options for patients with RT, checkpoint inhibition provides a potential therapeutic option. This trial is registered at www.clinicaltrials.gov as #NCT02420912.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008790","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:07:44Z","timestamp":1666796864000},"page":"1958-1966","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL"],"prefix":"10.1182","volume":"7","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5140-3633","authenticated-orcid":false,"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-7572","authenticated-orcid":false,"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-3833","authenticated-orcid":false,"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[{"name":"3Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-9769","authenticated-orcid":false,"given":"Erin","family":"Parry","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph","family":"Khoury","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[{"name":"5Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"6Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Lopez","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ayala","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"7Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Allison","sequence":"additional","affiliation":[{"name":"3Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"8Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[{"name":"3Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"8Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"9Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"issue":"5","key":"2023052315240922400_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of Chronic Lymphocytic Leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023052315240922400_bib2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2023052315240922400_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2016.1199948","article-title":"Richter transformation of CLL","volume":"9","author":"Jain","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"25","key":"2023052315240922400_bib4","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2023052315240922400_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Yucai","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"2023052315240922400_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O'Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023052315240922400_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2023052315240922400_bib8","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023052315240922400_bib9","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.3390\/cancers13205141","article-title":"Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents","volume":"13","author":"Tadmor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2023052315240922400_bib10","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023052315240922400_bib11","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023052315240922400_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023052315240922400_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023052315240922400_bib14","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2023052315240922400_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2023052315240922400_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2014.05.006","article-title":"Immunomodulation and immune reconstitution in chronic lymphocytic leukemia","volume":"51","author":"Riches","year":"2014","journal-title":"Semin Hematol"},{"issue":"2","key":"2023052315240922400_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023052315240922400_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2023052315240922400_bib19","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023052315240922400_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2023052315240922400_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"key":"2023052315240922400_bib22","doi-asserted-by":"crossref","first-page":"594841","DOI":"10.3389\/fimmu.2020.594841","article-title":"Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome","volume":"11","author":"Aug\u00e9","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"2023052315240922400_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023052315240922400_bib24","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"15","key":"2023052315240922400_bib25","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2023052315240922400_bib26","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023052315240922400_bib27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"2023052315240922400_bib28","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2023052315240922400_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr Clin Trials"},{"issue":"1","key":"2023052315240922400_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2023052315240922400_bib31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2023052315240922400_bib32","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"2023052315240922400_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A\u00a0single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2023052315240922400_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"issue":"2","key":"2023052315240922400_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2023052315240922400_bib36","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023052315240922400_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2023052315240922400_bib38","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/bmt.2017.158","article-title":"Association between GvHD and nivolumab in the FDA adverse event reporting system","volume":"52","author":"Oshima","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2023052315240922400_bib39","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023052315240922400_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"S2","key":"2023052315240922400_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/hon.41_2880","article-title":"Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent BTK inhibitor in previously treated richter transformation: results from the phase 1\/2 bruin study","volume":"39","author":"Jurczak","year":"2021","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2023052315240922400_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and Efficacy of CD19-CAR T Cells in Richter\u2019s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"2023052315240922400_bib43","doi-asserted-by":"crossref","first-page":"888109","DOI":"10.3389\/fonc.2022.888109","article-title":"Cellular Therapy in High-Risk Relapsed\/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome","volume":"12","author":"Barbanti","year":"2022","journal-title":"Front Oncol"},{"key":"2023052315240922400_bib44","article-title":"Emerging Therapies for the Management of Richter Transformation","author":"Smyth","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"2023052315240922400_bib45","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/1958\/2052303\/blooda_adv-2022-008790-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/1958\/2052303\/blooda_adv-2022-008790-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:38:52Z","timestamp":1684856332000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/10\/1958\/486897\/A-phase-2-study-of-nivolumab-combined-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008790","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}